Publications
- Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)2022 | First Faculty of Medicine
- NSCLC (Non-Small Cell Lung Cancer) and kidney tumor in the elderly patient with response to chemoimmunotherapy2021 | First Faculty of Medicine
- CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)2023 | First Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine
- Komentář ke studii2023 | First Faculty of Medicine
- CheckMate 9LA trial: commentary and clinical case report of patient with cerebellar metastasis2023 | First Faculty of Medicine
- Cemiplimab: monotherapy and combination therapy of NSCLC - analysis of locally advanced disease2023 | First Faculty of Medicine
- Immunotherapy associated pulmonary toxicity: pneumonitis2023 | First Faculty of Medicine
- Komentář k analýze2023 | First Faculty of Medicine
- Indikace durvalumabu v léčbě pacientů s bronchogenním karcinomem2023 | First Faculty of Medicine
- Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
Loading network view...